Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EMA Turns Down Minoryx’s Orphan Drug Nezglyal & Apellis’ Syfovre, OKs Three Others

26 Jan 2024

• By Eliza Slawther

Thumb up and thumb down — • Source: Shutterstock

Related Content

Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna

15 Sep 2023

EMA And FDA Compared – The Case Of Minoryx’s Leriglitazone

06 Jul 2023

Keeping Track: First-In-Class Candidates In COPD, Cancer Join US FDA Review Queue

16 Jul 2023

Apellis Awaits A European Rejection

15 Dec 2023

EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan

22 Jan 2024

EMA Considers Cardiovascular Indication & Extra Market Protection For Wegovy

23 Jan 2024

Related Companies

Minoryx Therapeutics

Apellis Pharmaceuticals, Inc.

PTC Therapeutics, Inc.

Allecra Therapeutics GmbH

Evive Biotech

Janssen-Cilag International

Novo Nordisk A/S

Additional Topics

Europe EU Approvals Drug Review Rare Diseases Regulation BioPharmaceutical Cancer Infectious Diseases Ophthalmic Neurology

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.